Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Completed 3

Sponsor Class

OTHER 27INDUSTRY 10NIH 3NETWORK 3

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 3Other hematologic neoplasm 2Classical hematology 1

Conditions

Breast Neoplasms 309Neoplasms 269Prostatic Neoplasms 189Precursor Cell Lymphoblastic Leukemia-Lymphoma 186Lymphoma 184Leukemia, Lymphocytic, Chronic, B-Cell 161Melanoma 158Leukemia 154Lymphoma, Non-Hodgkin 149Leukemia, Myeloid, Acute 149Brain Neoplasms 143Carcinoma, Non-Small-Cell Lung 141Lymphoma, Large B-Cell, Diffuse 128Colonic Neoplasms 128Lymphoma, Follicular 123Burkitt Lymphoma 119Ovarian Neoplasms 117Lung Neoplasms 116Glioblastoma 116Lymphoma, Mantle-Cell 114Unspecified Adult Solid Tumor, Protocol Specific 107Rectal Neoplasms 103Sarcoma 102Multiple Myeloma 102Gliosarcoma 102Hodgkin Disease 97Carcinoma, Renal Cell 97Lymphoma, B-Cell, Marginal Zone 96Astrocytoma 95Carcinoma, Ovarian Epithelial 93

Interventions

Melphalan 2Dexamethasone 1Calcium Dobesilate 1Bortezomib 1ARQ 197 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × NIH × Amyloidosis × Clear all
NCT01078454 2022-02-01

Melphalan and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Systemic Light-Chain Amyloidosis

National Cancer Institute (NCI)

Phase 3 Completed
11 enrolled 6 charts
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Amyloidosis

NCT01447914 2019-08-28

Tivantinib in Treating Patients With Relapsed, or Relapsed and Refractory Multiple Myeloma

National Cancer Institute (NCI)

Phase 2 Completed
16 enrolled 11 charts
Classical hematologyOther hematologic neoplasmPlasma cell

Amyloidosis, Anemia, Bone Diseases, Metabolic, Fractures, Spontaneous, Hypercalcemia, Multiple Myeloma, Osteolysis, Paraproteinemias, Hematologic Neoplasms, Renal Insufficiency

NCT00017680 2008-06-09

Study of High-Dose Melphalan and Autologous Stem Cell Transplantation in Patients With Primary Light Chain Amyloidosis

Office of Rare Diseases (ORD)

Phase 2 Completed
25 enrolled
Other hematologic neoplasmPlasma cell

Immunoglobulin Light-chain Amyloidosis, Amyloidosis, Arthritis, Connective Tissue Diseases, Hematologic Neoplasms, Genetic Diseases, Inborn, Rare Diseases, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡